Comparative Pharmacology
Head-to-head clinical analysis: CINOBAC versus NALIDIXIC ACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CINOBAC versus NALIDIXIC ACID.
CINOBAC vs NALIDIXIC ACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cinobufagin, a bufadienolide from toad venom, inhibits Na+/K+-ATPase, leading to increased intracellular calcium, and also induces apoptosis via caspase activation and modulation of signal transduction pathways including PI3K/Akt and MAPK.
Nalidixic acid is a first-generation quinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, and repair. It exhibits bactericidal activity primarily against Gram-negative bacteria.
250 mg orally twice daily for 7-14 days
1 g orally every 6 hours for 7-14 days. For uncomplicated urinary tract infections, 1 g orally every 12 hours may be sufficient.
None Documented
None Documented
Clinical Note
moderateNalidixic acid + Digoxin
"Nalidixic acid may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateNalidixic acid + Digitoxin
"Nalidixic acid may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateNalidixic acid + Deslanoside
"Nalidixic acid may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateNalidixic acid + Acetyldigitoxin
"Nalidixic acid may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function; may be prolonged up to 8-12 hours in severe renal impairment (CrCl <30 mL/min).
Terminal half-life is approximately 1-2.5 hours in adults with normal renal function. In patients with renal impairment (CrCl <20 mL/min), half-life may be prolonged to 6-21 hours, requiring dose adjustment.
Renal excretion of unchanged drug accounts for approximately 85-90% of elimination, with 10-15% metabolized hepatically to inactive glucuronide conjugates excreted in urine. Less than 2% is eliminated in feces via biliary excretion.
Primarily renal (80-90% as unchanged drug and active metabolites, including hydroxynalidixic acid and dicarboxylic acid derivative); minimal biliary (<5%) and fecal (<5%) excretion.
Category C
Category C
Quinolone Antibiotic
Quinolone Antibiotic